Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising stocks with huge upside potential. On November 24, Barclays analyst Gena Wang lowered the firm’s price target on Ultragenyx (RARE) to $50 from $81 and maintained an Overweight rating on the shares. The firm lowered its price target following analysis of the setrusumab COSMIC study, but still maintains an over 70% chance of a positive result.

Earlier the same month, Ultragenyx Pharmaceutical reported that it made a total revenue of $160 million in Q3 2025, which marked a 15% growth year-over-year. The company is now on track to deliver full-year revenue between $640 and $670 million, which represents a growth of 14% to 20% over 2024. Revenue growth was driven by its key commercial products. Crysvita Revenue accounted for $112 million in Q3. The full-year Crysvita revenue guidance is expected between $460 and $480 million, a 12% to 17% growth over 2024, despite the short-term impact from expected seasonality on royalty revenue. AJOVY Revenue for the quarter was $24 million, and Mepsevii Revenue was $7 million.

The company also reported a net loss of $180 million or $1.81 per share for Q3. Ultragenyx is now aggressively advancing multiple late-stage clinical programs with transformative commercial potential, including UX 143 (setrusumab) and GTX-102. Submissions for other pipeline assets are also on track, with DTX401 expected for submission next month, while the submission for UX 111 was slightly delayed due to requirements for additional reports.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company that identifies, acquires, develops, and commercializes novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.